...Cambridge MA April 9 2013 BIND Therapeutics a clinical-stage bioph...Clinical investigators presented the Phase 1 results with BIND-014 it... This Phase 1 trial has successfully established the safety and tolera... In addition to confirming the safety tolerability and maximum tolera...

Cambridge, MA, April 9, 2013 BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, announced today that positive Phase 1 clinical data for BIND-014, the company's lead drug candidate, were presented today in an oral presentation at the American Association for Cancer Research (AACR) 2013 Annual Meeting.

Clinical investigators presented the Phase 1 results with BIND-014, its targeted docetaxel Accurin, in 28 heavily-pretreated patients with advanced or metastatic solid tumors. In the study, BIND-014 was shown to be generally safe and well-tolerated at the established maximum tolerated dose of 60 mg/m2 and showed encouraging signs of anti-tumor activity including one complete response, three partial responses and five patients with stable disease lasting at least four cycles (> 12 weeks). In addition, the pharmacokinetic (PK) profile of BIND-014 was substantially different from the published PK of conventional docetaxel.

"This Phase 1 trial has successfully established the safety and tolerability profile and maximum tolerated dose of BIND-014 in patients with advanced or metastatic solid tumor cancers," commented Daniel D. Von Hoff, M.D., F.A.C.P., Principal Investigator for the study and Physician-in-Chief and Distinguished Professor at the Translational Genomics Research Institute (TGen) and the Scottsdale Clinical Research Institute. "There is a critical need for targeted treatment options for patients with difficult to treat solid tumors and we look forward to further evaluating the potential of BIND-014 in patients with specific solid tumor types in the near future."

"In addition to confirming the safety, tolerability and maximum tolerated dose of BIND-014, these data also provide encouraging signs of anti-tumor activity in a variety of solid tumors," said Gregory Berk, M.D., Chief Medical Officer of BIND Therapeutics. "Based on these dat'/>"/>

(Date:3/3/2015)... US Air Purifiers LLC , an Illinois based ... to announce that all Rabbit brand air purifiers are back ... west coast port strikes. This news comes just in time, ... The port strikes, which have caused significant supply ... growth by as much as 1%, have hindered the restocking ...

(Date:3/3/2015)... March 03, 2015 Daylight Savings Time may ... Kothare, MD, has tips for parents. , Parents and their ... at 2:00 a.m. when they set their clocks forward one ... up that day -- one hour earlier -- you will ... parents should start thinking about “sleep hygiene” for their kids ...

(Date:3/3/2015)... Rhinebeck, NY (PRWEB) March 03, 2015 Topical ... held as a webinar streamed live on Tuesday, March 10th, ... workshops will be archived and accessible 24/7. ... the public. The topic for the March 10th workshop is ... timely discussion, considering that the U.S. represents 5% of the ...

(Date:3/3/2015)... MD (PRWEB) March 03, 2015 Today ... Association (ASHA) is using the occasion to applaud and ... campaign by the World Health Organization (WHO) for stemming ... campaign aims to encourage young people to practice safe ... audio technology, attending concerts or sporting events, or engaging ...

(Date:3/3/2015)... Mason, OH (PRWEB) March 03, 2015 ... found to better predict antidepressant treatment outcomes for ... care resources, than any of the individual genes ... analysis by investigators from the Mayo Clinic and ... Journal i. , The proprietary technology of ...

... ANGELES, Sept. 24 LA Animal Services is reminding,all Los ... with the,City,s new spay/neuter law before formal enforcement begins on ... of Los Angeles approved a new,law that requires all cats ... the age of four months, with some specific exemptions allowed. ...

... The U.S. Pharmacopeial (USP) Convention is pleased to ... Material (CRM), Dextromethorphan Hydrobromide. USP recently became the ... Standardization accreditation as producer of chemical CRMs. ... new class of reference standard that ensures improved ...

... incidence of liver cirrhosis is still high, although ... is no established therapy for liver fibrosis, and ... Qianggan-Rongxian Soup on liver fibrosis induced by DMN ... hepatic fibrosis resulted from chronic liver injure, retard ...

... finest local physicians for new ... Chicago practice, BELLEVUE, ... Chicago practice with two of the,area,s finest primary care physicians. With 30 ... for the company to seek its,next two physicians and expand its network., ...

... The nation,s,leading association for professionally managed assisted ... the end of life choices,made by aging Americans., ... the Assisted Living Federation,of America (ALFA), said the ... for them in testimony submitted to the Senate ...

... Pay An Average Of $3,354 Annually Toward Family Coverage, ... Growing Shares of Workers Now Face Deductibles Of At ... Covered By Smaller Firms, WASHINGTON, Sept. 24 ... family,coverage this year -- with employees on average paying ...

(Date:3/3/2015)... 2015 Registration is officially open for MEDTEC China ... at the Shenzhen Convention & Exhibition Center. The ... to join the MEDTEC China family of events. MEDTEC China ... to better serve the South China ... an important region for China,s medical ...

(Date:3/3/2015)... and BETHESDA, Md. , March ... with the first stem cell-derived islet replacement therapy for ... a presentation by Dr. Eugene Brandon , Director ... TypeOneNation Summit. The annual summit showcases the latest in ... Details of the presentation are as follows: , ...

... of Dimes Concerned About Drugs, Role in Crisis of Prematurity , ... WHITE PLAINS, N.Y. , June 16 The widespread use ... births and contributes to the problem of premature birth in the United States , ... , , ...

... BELGRADE, Mont. , June 16 ... graft material, today announced a three-year agreement to ... OsteoSponge SC®, OsteoWrap®, BacFast®, and OsteoLock®, to the ... practices. The group purchasing agreement through which any ...

... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...